Shares of telehealth company Hims &amp; Hers Health (HIMS.N) fall 4% to $16.01 in afternoon trading, on track for their tenth straight day of losses Last week, HIMS said it would launch a $49 compounded version of Novo Nordisk’s Wegovy pill for weight loss, which was then withdrawn after scrutiny from the U.S. health regulator Co’s shares fell further after Danish drugmaker Novo sued HIMS over patent infringement of semaglutide, the active ingredient in Wegovy
Novo has sued several compounders for allegedly selling unsafe, falsely advertised Wegovy “knockoffs” that violate its trademark rights, but the Hims lawsuit is its first U.S. patent case against a compounder
Up to last close, HIMS down 50% YTD

IBBQ

Shares of Hims & Hers Healthfell 4% to $16.01, marking the company's tenth consecutive day of losses. This decline follows the announcement of a $49 compounded version of Novo Nordisk’s Wegovy pill for weight loss, which was later withdrawn due to regulatory scrutiny. Additionally, HIMS faces a lawsuit from Novo for patent infringement related to semaglutide, the active ingredient in Wegovy. Year-to-date, HIMS shares have decreased by 50%.

Reuters

iShares US Pharma

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Health

Defiance Leveraged Long +Income HIMS ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Hims & Hers Health

SPDR S&P Health Equip

Defiance Daily Target 2X Long HIMS ETF

iShares US Healthcare Providers

Novo Nordisk AS

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

ALPS Medical Breakthrough

VG Health

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

BUZZ-Hims & Hers falls, set for tenth straight day of losses